It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACAD’s FA Score shows that 1 FA rating(s) are green whileOKTA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACAD’s TA Score shows that 5 TA indicator(s) are bullish while OKTA’s TA Score has 5 bullish TA indicator(s).
ACAD (@Biotechnology) experienced а +0.33% price change this week, while OKTA (@Computer Communications) price change was +1.03% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +8.01%. For the same industry, the average monthly price growth was +21.26%, and the average quarterly price growth was +88.68%.
The average weekly price growth across all stocks in the @Computer Communications industry was +1.17%. For the same industry, the average monthly price growth was +10.18%, and the average quarterly price growth was +68.70%.
ACAD is expected to report earnings on Nov 11, 2025.
OKTA is expected to report earnings on Dec 03, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Computer Communications (+1.17% weekly)Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
ACAD | OKTA | ACAD / OKTA | |
Capitalization | 3.6B | 16.3B | 22% |
EBITDA | 104M | 281M | 37% |
Gain YTD | 16.131 | 17.551 | 92% |
P/E Ratio | 16.02 | 110.27 | 15% |
Revenue | 1.02B | 2.76B | 37% |
Total Cash | 762M | 2.86B | 27% |
Total Debt | 56.3M | 940M | 6% |
ACAD | OKTA | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 29 | 89 | |
PRICE GROWTH RATING 1..100 | 49 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ACAD's Valuation (66) in the Biotechnology industry is in the same range as OKTA (81) in the Packaged Software industry. This means that ACAD’s stock grew similarly to OKTA’s over the last 12 months.
ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OKTA (100) in the Packaged Software industry. This means that ACAD’s stock grew similarly to OKTA’s over the last 12 months.
ACAD's SMR Rating (29) in the Biotechnology industry is somewhat better than the same rating for OKTA (89) in the Packaged Software industry. This means that ACAD’s stock grew somewhat faster than OKTA’s over the last 12 months.
ACAD's Price Growth Rating (49) in the Biotechnology industry is in the same range as OKTA (59) in the Packaged Software industry. This means that ACAD’s stock grew similarly to OKTA’s over the last 12 months.
ACAD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as OKTA (100) in the Packaged Software industry. This means that ACAD’s stock grew similarly to OKTA’s over the last 12 months.
ACAD | OKTA | |
---|---|---|
RSI ODDS (%) | 2 days ago64% | N/A |
Stochastic ODDS (%) | 2 days ago75% | 2 days ago81% |
Momentum ODDS (%) | 2 days ago78% | 2 days ago82% |
MACD ODDS (%) | N/A | N/A |
TrendWeek ODDS (%) | 2 days ago75% | 2 days ago74% |
TrendMonth ODDS (%) | 2 days ago74% | 2 days ago68% |
Advances ODDS (%) | 7 days ago73% | 22 days ago76% |
Declines ODDS (%) | 2 days ago70% | 9 days ago72% |
BollingerBands ODDS (%) | 2 days ago76% | 2 days ago90% |
Aroon ODDS (%) | 2 days ago73% | 2 days ago74% |